Surmodics, Inc. (SRDX)
Largest Insider Buys in Sector
SRDX Stock Price History Chart
SRDX Stock Performance
About Surmodics, Inc.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to …
Insider Activity of Surmodics, Inc.
Over the last 12 months, insiders at Surmodics, Inc. have bought $0 and sold $276,453 worth of Surmodics, Inc. stock.
On average, over the past 5 years, insiders at Surmodics, Inc. have bought $0 and sold $1.45M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,500 shares for transaction amount of $30,536 was made by KNIGHT SUSAN E (director) on 2014‑05‑08.
List of Insider Buy and Sell Transactions, Surmodics, Inc.
| 2024-11-26 | Sale | Chief Financial Officer | 7,009 0.0488% | $39.44 | $276,453 | +0.91% | ||
| 2022-11-28 | Sale | director | 4,366 0.0314% | $34.89 | $152,321 | -13.40% | ||
| 2022-11-14 | Sale | director | 2,773 0.0191% | $33.00 | $91,507 | -12.13% | ||
| 2022-11-11 | Sale | director | 2,733 0.0195% | $33.48 | $91,511 | -10.24% | ||
| 2022-04-01 | Sale | President & CEO | 100 0.0007% | $45.55 | $4,555 | -22.80% | ||
| 2022-02-28 | Sale | director | 4,366 0.0314% | $44.97 | $196,332 | -20.68% | ||
| 2022-01-04 | Sale | SVP, HR and GM, IVD | 2,500 0.0186% | $50.00 | $125,000 | -24.02% | ||
| 2021-11-30 | Sale | director | 5,576 0.0402% | $44.00 | $245,350 | -13.64% | ||
| 2021-11-24 | Sale | director | 3,475 0.0246% | $47.01 | $163,360 | -20.31% | ||
| 2021-11-01 | Sale | President & CEO | 6,000 0.0434% | $54.65 | $327,904 | -27.75% | ||
| 2021-10-01 | Sale | President & CEO | 6,000 0.0428% | $56.02 | $336,097 | -25.26% | ||
| 2021-09-15 | Sale | President & CEO | 6,000 0.0431% | $57.23 | $343,359 | -25.74% | ||
| 2021-08-31 | Sale | Senior VP of Bus Dev, Med Dev | 1,292 0.0093% | $59.75 | $77,197 | -28.08% | ||
| 2021-08-19 | Sale | SVP, HR and GM, IVD | 2,500 0.0179% | $54.40 | $136,002 | -20.79% | ||
| 2021-08-11 | Sale | Corporate Controller | 2,608 0.0187% | $53.35 | $139,136 | -18.53% | ||
| 2021-05-20 | Sale | SVP, HR and GM, IVD | 2,500 0.0181% | $53.80 | $134,506 | -9.08% | ||
| 2021-04-28 | Sale | Senior VP of Bus Dev, Med Dev | 1,508 0.011% | $59.75 | $90,103 | -10.93% | ||
| 2021-04-16 | Sale | Senior VP of Bus Dev, Med Dev | 648 0.0048% | $59.75 | $38,718 | -8.87% | ||
| 2021-03-31 | Sale | Senior VP of Bus Dev, Med Dev | 4,759 0.0348% | $56.75 | $270,073 | -4.74% | ||
| 2021-03-01 | Sale | President & CEO | 4,000 0.0286% | $52.06 | $208,259 | +1.58% |
Insider Historical Profitability
| DANTZKER DAVID | director | 34178 0.2391% | $39.50 | 1 | 3 | <0.0001% |
| KNIGHT SUSAN E | director | 30196 0.2112% | $39.50 | 2 | 6 | +11.09% |
| BUHRMASTER ROBERT C | director | 2625 0.0184% | $39.50 | 1 | 0 | +18.46% |
Institutional Investor Ownership
| Trigran Investments, Inc. | $69.19M | 16.54 | 2.36M | 0% | +$0 | 6.71 | |
| BlackRock | $30.86M | 7.38 | 1.05M | -2.62% | -$831,114.19 | <0.01 | |
| The Vanguard Group | $25.39M | 6.07 | 865,214 | +0.69% | +$173,898.17 | <0.0001 | |
| Morgan Stanley | $25.05M | 5.99 | 853,915 | -31.23% | -$11.38M | <0.01 | |
| Soleus Capital Management, L.P. | $23.5M | 5.62 | 800,820 | +3.77% | +$854,380.81 | 0.1 |